SAB Biotherapeutics (SABS) Earnings Date & Reports

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

SABS is expected to report earnings to rise 48.80% to -83 cents per share on March 28

SAB Biotherapeutics SABS Stock Earnings Reports

Q4'23

Est.

$-0.83

Q1'25

Missed

by $0.44

Q3'23

Missed

by $0.88

Q2'23

Missed

by $1.26

Q1'23

Missed

by $1.39

The last earnings report on May 09 showed earnings per share of -56 cents, missing the estimate of -11 cents. With 18.81K shares outstanding, the current market capitalization sits at 16.07M.

View a ticker or compare two or three

Compare

SABS